Revance completes enrollment in Phase II trial of RT002 to treat plantar fasciitis

Revance Therapeutics Inc. (NASDAQ:RVNC) completed enrollment of 59 patients in a Phase II trial of daxibotulinumtoxinA for injection (RT002) to treat plantar fasciitis. The double-blind, placebo-controlled, U.S. trial is evaluating single injections of 240 units of RT002. The primary endpoint is reduction in foot pain at week 8 as measured by the visual analog scale (VAS). Secondary endpoints include reduction in foot pain at week 16, American Orthopedic Foot and Ankle Score (AOFAS) and patient-reported outcomes...